Genentech-Roche's Avastin wins FDA nod for cervical cancer

08/15/2014 | Medscape (free registration)

Genentech and Roche Holding obtained the FDA's approval to market Avastin, or bevacizumab, as a treatment for recurrent, persistent or late-stage cervical cancer. The drug is to be given with paclitaxel in combination with cisplatin or topotecan. Avastin is already cleared for the treatment of four types of cancer.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN